NewAmsterdam's Obicetrapib Clears Key EU Hurdle with Positive CHMP Opinion
NAMS sits 48% above its 52-week low of $21.135.
Summary
NewAmsterdam Pharma and partner Menarini received a positive CHMP opinion for obicetrapib monotherapy and its fixed-dose combination with ezetimibe, recommending EU marketing authorization. A final European Commission decision is expected in 2H26, triggering potential milestone payments and royalties.
Key Events · Product Development and Regulatory · NAMS
-
CHMP Recommends EU Approval
The EMA's CHMP adopted a positive opinion for Ubeslo® (obicetrapib monotherapy) and Evlarco® (obicetrapib/ezetimibe FDC) for primary hypercholesterolemia and mixed dyslipidemia, based on Phase 3 BROADWAY, BROOKLYN, and TANDEM data.
-
Commercial Opportunity in Europe
Menarini holds exclusive European commercialization rights; NewAmsterdam is entitled to tiered double-digit royalties (low double-digits to mid-twenties) and up to €833 million in clinical, regulatory, and commercial milestones.
-
Next Regulatory Step
The European Commission is expected to issue a final marketing authorization decision in the second half of 2026, which would apply across all EU member states plus Iceland, Liechtenstein, and Norway.
-
Clinical Validation
Obicetrapib demonstrated statistically significant LDL-C reductions of up to 40% as monotherapy and ~50% in combination with ezetimibe versus placebo, with a tolerability profile comparable to placebo.
Analysis · NAMS · Life Sciences
A positive CHMP opinion marks a pivotal regulatory milestone, placing obicetrapib on the cusp of EU marketing authorization. As the drug's first major regulatory decision, it validates the clinical profile and unlocks a path to commercialization in Europe. With a final European Commission decision expected in the second half of 2026, the event materially de-risks the obicetrapib program and opens a significant revenue stream through partner Menarini, including up to €833 million in milestones and tiered double-digit royalties. For a late-stage biotech with a $3.6 billion market cap, this is a thesis-altering event that shifts the focus from clinical development to commercial execution.
How filings like this one have moved
In the 30 days to Sep 16, 2026, 39.8% of the 397 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.50%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, NAMS was trading at $31.35 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.6B. The 52-week trading range was $21.14 to $42.21. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.